On October 22, 2025, Arcturus Therapeutics Holdings announced interim Phase 2 clinical results for ARCT-032, its investigational inhaled mRNA therapy for cystic fibrosis, sharing details on mucus ...
Shares of Arcturus Therapeutics Holdings fell sharply premarket amid fears about patient complications in the wake of a mid-stage trial of a biotech spray treatment for cystic fibrosis that had mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback